Bristol-Myers subpoenaed on Abilify marketing; Corcept wins FDA approval for Korlym;

@FiercePharma: New M&A regs won't put a damper on Indian pharma deals, survey finds. More | Follow @FiercePharma

> The U.S. Attorney's Office in New York issued a subpoena to Bristol-Myers Squibb ($BMY), asking for information about the company's marketing of the antipsychotic drug Abilify. Report

> Corcept Therapeutics won the FDA's nod for Korlym, the first oral drug to treat the endocrine disorder Cushing's syndrome. Article

> European regulators approved Roche's ($RHHBY) targeted melanoma drug Zelboraf, which analysts expect to peak at $1.3 billion in global sales. More

> AstraZeneca ($AZN) won the European Commission's blessing for Caprelsa as a treatment for a form of thyroid cancer. News

> U.S.-based generics maker Mylan ($MYL) beat analyst estimates with its $129.5 million in fourth-quarter profits, aided by sales of new products in North America. Report

> Bayer's eye drug Eylea, approved for wet AMD last fall, helped patients see better in a long-term study of the drug as a treatment for central retinal vein occlusion. Article

Biotech News

@FierceBiotech: Google software could aid drug design. Article | Follow @FierceBiotech

@JohnCFierce: Dealmaking rule no. 1: always claim to have multiple bidders interested in a product. Like Biotie on Alzheimer's program. More | Follow @JohnCFierce

@RyanMFierce: Here's my take and some inside dope one of biopharma's hottest job markets. Piece | Follow @RyanMFierce

@MarkHFierce: I'll start with something slightly off topic because it is so unbelievably cool. Scientists sprout an ancient plant. Story | Follow @MarkHFierce

> Novartis snags preclinical hep C drug in $440M Enanta pact. News

> FDA staffers advise agency to deny Chelsea's key drug. More

> Pfizer amps up R&D partnering activity in China and India. Story

> Threshold shares spike on positive IIb data for pancreatic cancer drug. Report

> GTx shares tumble after clot threat forces hold on prostate cancer drug. Article

> FDA raises cardio concerns on Forest's new COPD drug. Item

IT News

> Oracle aids Moffitt Cancer Center’s IT system for speeding patient recruitment. Article

> Global Alzheimer's researchers seek cloud-based infrastructure to share data. News

> Eisai's H3 Biomedicine taps cancer genomics software for drug discovery effort. More

> Big Pharma activity eyed in mobile trends. Item

Manufacturing News

> Hospira on track with expansions in India. Story

> Leader of Pakistan drugmakers resigns in frustration. News

> Avastin alert likely to revive discussion of pharma-financed tracking system. Article

> UPDATED: Teva halts production of drug in U.K. Item

Research News

> Engineered measles virus prolongs lifespan of brain cancer-stricken mice. More

> Amniotic stem cells boost kidney disease survival time. Story

> Tobacco-chewing may damage crucial gene. Item

> Humans to test T-cell treatment that subdued canine lymphoma. Article

> Flu, over time, could increase Alzheimer's vulnerability. Piece

> Can omega-3 fatty acids beat back cancer? Maybe not. More

And Finally... Strong demand for Swiss-made pharmaceuticals pushed the country's exports higher despite its strong currency. Report